Atlas Trials

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Clinical trial NCT04616534 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04616534
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic AdenocarcinomaAdvanced Primary Peritoneal CarcinomaFallopian Tube High Grade Serous AdenocarcinomaMetastatic Pancreatic AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPrimary Peritoneal High Grade Serous Adenocarcinoma
Start date
2021-06-01
Primary completion
2025-04-01
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.